Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 8/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1986946 | 0.85 | PARP1 (0.43) | SRD5A1CA1CA2CA7CA9 | |
| SCHEMBL5106774 | 0.77 | METAP1 (0.44) | SRD5A1PARP1PARP10MAOBMAOA | |
| SCHEMBL8474486 | 0.77 | METAP1 (0.44) | SRD5A1CA1CA2CA7CA9 | |
| SCHEMBL2818053 | 0.77 | TDP2 (0.43) | MAOBMAOATDP2HSD17B10CASP1 | |
| SCHEMBL29726050 | 0.74 | CASP1 (0.59) | SRD5A1MAOBMAOAHSD17B1HSD17B10 | |
| SCHEMBL192610 | 0.74 | CASP1 (0.59) | SRD5A1MAOBMAOAHSD17B1HSD17B10 | |
| SCHEMBL2819249 | 0.73 | HTR2A (0.42) | CA1CA2MAOBMAOA | |
| SCHEMBL972858 | 0.73 | METAP1 (0.50) | CA1CA2CA7CA9ACHE | |
| SCHEMBL8162469 | 0.73 | TDP2 (0.49) | SRD5A1PARP10MAOBMAOATDP2 | |
| SCHEMBL1984962 | 0.71 | ACHE (0.54) | CA9PARP1ACHEPARP10MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384960-B2 | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-06-10 | — | — | US | disclosed |
| US-20050192332-A1 | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2005-09-01 | — | — | US | disclosed |
| US-6906080-B1 | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2005-06-14 | — | — | US | disclosed |
| EP-1230244-B1 | PYRAZOLECARBOXYLIC ACID TRICYCLIC DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2005-01-19 | — | — | EP | disclosed |
| EP-1230244-A2 | PYRAZOLECARBOXYLIC ACID TRICYCLIC DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Sanofi-Aventis (FR) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001032663-A2 | PYRAZOLECARBOXYLIC ACID TRICYCLIC DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2001-05-10 | — | — | WO | disclosed |
| US-5886016-A | ANTIINFLAMMATORY AGENT WITH MINIMAL SIDE EFFECTS FOR TREATING ARTHRITIS | G.D. SEARLE & CO. (US) | 1999-03-23 | — | — | US | disclosed |
| WO-1996009304-A1 | BENZOPYRANOPYRAZOLYL DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192332-A1 | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same | CNR1, CNR2, CBR3 | SRD5A1 562/4885CA1 1572/4885CA2 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.